Cartalax

Cartalax is a synthetic short peptide bioregulator corresponding to the tripeptide Ala-Glu-Asp (AED), one of the tissue-specific short peptides developed within the St. Petersburg school of bioregulation and gerontology associated with Vladimir Khavinson ^[1][5]. Like others in this family, it is a very small molecule, three amino acids in length, engineered to act as a signaling peptide that influences cellular activity rather than as a conventional receptor drug.

The short peptides of this class, generally two to seven residues long, are studied for their ability to penetrate cells and their nuclei and to regulate gene expression and protein synthesis; AED specifically has been examined across skin, neuronal, kidney, and stem cell models ^[1][2][3][4]. Because these effects appear at very low, nanomolar concentrations and resemble the action of endogenous signaling molecules, the peptides are described as epigenetic regulators of cell function ^[3][5].

Cartalax's research applications center on geroprotection, tissue renewal, and the study of cellular aging, where AED has been used to modulate proliferation, differentiation, apoptosis, and senescence markers ^[1][4]. Within the commercial peptide-bioregulator family its name evokes cartilage and connective tissue, and it is marketed as a tissue-support preparation. It is not an approved pharmaceutical in Western countries and is handled as a research or supplement peptide, typically supplied as a lyophilized powder or in capsule form.

Human safety data are limited. The Khavinson short-peptide bioregulators are generally described as low-toxicity in the Russian literature, but rigorous independent safety studies are lacking and long-term effects are uncharacterized. Investigational, research-only.

Cartalax is the synthetic tripeptide Ala-Glu-Asp (AED), one of the short peptide bioregulators developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, part of a research program that grew out of Soviet-era work on tissue-specific peptide regulation. Within this family, Cartalax was framed as a peptide directed at vascular and inflammatory tone, complementing other tissue-targeted members such as the pineal and thymic peptides.

Its characterization has proceeded largely through cell-culture and molecular studies of gene expression, senescence markers, and cell differentiation, published mainly in the Russian and specialist gerontology literature. Compared with mainstream pharmaceuticals its development record is relatively sparse and concentrated in in vitro work, and no large clinical trial program is documented in the peer-reviewed literature.

Cartalax draws interest as a member of a celebrated and much-discussed family of Russian peptide bioregulators studied for cellular renewal and healthy aging, a lineage that has attracted a dedicated following among longevity enthusiasts. Its appeal lies in an elegant proposed mechanism: acting at the level of gene expression, the AED peptide has been shown in cell models to reduce markers of senescence and support proliferation, and related peptides can even bias stem cells toward neuronal differentiation. Supporters value that a molecule of just three amino acids can exert such specific transcriptional effects. In fairness, the evidence base is predominantly preclinical and laboratory-based, so it is best understood as a scientifically intriguing peptide with promising cellular data rather than clinically proven outcomes.